Lene Meldgaard Knudsen
Overview
Explore the profile of Lene Meldgaard Knudsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jorgensen N, Klausen U, Grauslund J, Helleberg C, Aagaard T, Hieu Do T, et al.
Front Immunol
. 2020 Nov;
11:595035.
PMID: 33240282
Background: Immune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have...
2.
Holmstrom M, Klausen U, Jorgensen N, Holmberg S, Grauslund J, Met O, et al.
Ugeskr Laeger
. 2019 Mar;
181(10).
PMID: 30869069
Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that...
3.
Juul M, Jensen P, Engberg H, Wehberg S, Dessau-Arp A, Haziri D, et al.
Eur J Cancer
. 2018 Jun;
99:86-96.
PMID: 29935491
Background: Optimal treatment strategy for the oldest patients with diffuse large B-cell lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical trials, and population-based studies are limited....
4.
Jorgensen N, Ahmad S, Abildgaard N, Straten P, Marie Svane I, Andersen M, et al.
Stem Cell Investig
. 2017 Jan;
3:95.
PMID: 28078275
The B-cell lymphoma-2 (Bcl-2) family of proteins play a crucial role in multiple myeloma (MM), contributing to lacking apoptosis which is a hallmark of the disease. This makes the Bcl-2...
5.
Petersen H, Holdgaard P, Madsen P, Knudsen L, Gad D, Gravergaard A, et al.
Eur J Nucl Med Mol Imaging
. 2015 Nov;
43(4):695-706.
PMID: 26519292
Purpose: The Region of Southern Denmark (RSD), covering 1.2 of Denmark's 5.6 million inhabitants, established a task force to (1) retrieve literature evidence for the clinical use of positron emission...
6.
Kristensen I, Haaber J, Lyng M, Knudsen L, Rasmussen T, Ditzel H, et al.
Leuk Lymphoma
. 2012 Jun;
54(2):425-7.
PMID: 22742577
No abstract available.
7.
Hjorth M, Hjertner O, Knudsen L, Gulbrandsen N, Holmberg E, Pedersen P, et al.
Eur J Haematol
. 2012 Mar;
88(6):485-96.
PMID: 22404182
Objectives: Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published...
8.
Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al.
Lancet Oncol
. 2010 Sep;
11(10):973-82.
PMID: 20863761
Background: Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest...
9.
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B, et al.
Blood
. 2010 May;
116(9):1405-12.
PMID: 20448107
In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was...
10.
Haaber J, Abildgaard N, Knudsen L, Dahl I, Lodahl M, Thomassen M, et al.
Br J Haematol
. 2007 Nov;
140(1):25-35.
PMID: 18005268
Osteolytic bone disease (OBD) in multiple myeloma (MM) is caused by interactions between MM cells and the bone marrow microenvironment and is characterized by increased osteoclastic bone resorption and decreased...